Abstract
Diabetes mellitus is a chronic metabolic disease affected a wide range of population all over the world and leads to development of many severe long term complications. Aldose reductase (AR) is the enzyme considered to play a key role in the development of secondary diabetic complications via polyol pathway. AR inhibition has been proposed as a strategy to prevent and delayed such complications. 2,4-thiazolidinedione derivatives being isosteres of hydantoin, emerged as potential AR inhibitors with antidiabetic activity. Therefore, we have designed novel arylidene-2, 4-thiazolidinediones as AR inhibitors using molecular docking technique. Mol-dock score along with re-rank score was the criteria for measuring the affinity of STMG-(1-40) with the AR enzymes. Result of present study will provide a new guideline for the further design of novel potent inhibitors of AR in the management of diabetes along with its complications.
Keywords: Diabetic complications, Diabetes, Docking, Aldose reductase, Nephropathy, Thiazolidinedione.
Letters in Drug Design & Discovery
Title:Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Volume: 10 Issue: 7
Author(s): Manoj Kumar Gautam and Suresh Thareja
Affiliation:
Keywords: Diabetic complications, Diabetes, Docking, Aldose reductase, Nephropathy, Thiazolidinedione.
Abstract: Diabetes mellitus is a chronic metabolic disease affected a wide range of population all over the world and leads to development of many severe long term complications. Aldose reductase (AR) is the enzyme considered to play a key role in the development of secondary diabetic complications via polyol pathway. AR inhibition has been proposed as a strategy to prevent and delayed such complications. 2,4-thiazolidinedione derivatives being isosteres of hydantoin, emerged as potential AR inhibitors with antidiabetic activity. Therefore, we have designed novel arylidene-2, 4-thiazolidinediones as AR inhibitors using molecular docking technique. Mol-dock score along with re-rank score was the criteria for measuring the affinity of STMG-(1-40) with the AR enzymes. Result of present study will provide a new guideline for the further design of novel potent inhibitors of AR in the management of diabetes along with its complications.
Export Options
About this article
Cite this article as:
Gautam Kumar Manoj and Thareja Suresh, Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors, Letters in Drug Design & Discovery 2013; 10 (7) . https://dx.doi.org/10.2174/1570180811310070007
DOI https://dx.doi.org/10.2174/1570180811310070007 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes
Current Diabetes Reviews Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers
Current Pharmaceutical Design Beneficial Effects of Dietary Supplements Against Mitochondrial Dysfunction and Apoptosis in Neurodegenerative Diseases
Current Pharmacogenomics and Personalized Medicine Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Role of Reactive Oxygen Species in Estrogen Dependant Breast Cancer Complication
Anti-Cancer Agents in Medicinal Chemistry